Surgical Science Sweden AB

Surgical Science Sweden AB

SUS · ST · Healthcare / Health Information Services

56.45SEK+0.85 (+1.53%)

Price History

Full chart

Market Stats

Previous Close55.60
Open56.20
Day Range54.75 – 57.35
52-Week Range23.70 – 94.70
Volume423.49K
Market Cap2.72B
P/E (TTM)29.92
Forward P/E14.18
EPS1.78
Dividend Yield0.00%
Beta0.64
50-Day Avg45.60
200-Day Avg34.99

About

Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training; URO Mentor, a virtual reality simulator for endourology training; EndoSim, a realistic scope simulator; FlexVR, a flexible and portable training platform which is designed to teach basic and advanced skills for robotic surgery; and LAP Mentor provides a wide array of laparoscopic training cases. It also provides LapSim training system comprising LapSim Haptic simulator that provides laparoscopic training; LapSim essence, a portable and ready-to-use VR simulator; and LapSim 360, which provides a high-immersion virtual reality training experience; MentorLearn, an end-to-end educational platform that makes simulation course management; and LapSim ST, a training system that prepares students for the operating room. In addition, the company offers PELVIC Mentor simulator provides anatomy and pelvic exam training; Perc Mentor suite for image-guided interventions; RobotiX Mentor for practice the motor and cognitive skills for surgeons; Simball Box, which combines with digitally collected metrics into a training tool; Spine Mentor, a training simulator for minimal invasive spine surgery; TEE Express, designed to teach Trans-Esophageal Echocardiography procedure using a TEE probe; TraumaVR, an ultimate mix of manikin and VR simulation; and Ultrasound Mentor for ultrasound training with multiple medical specialties. Surgical Science AB was founded in 1997 and is based in Gothenburg, Sweden.

Company Details

  • SectorHealthcare
  • IndustryHealth Information Services
  • CEOMr. Tom Englund
  • Employees319
  • HeadquartersDrakegatan 7A, Gothenburg, Sweden, 412 50, Sweden
  • Websitehttps://www.surgicalscience.com

Leadership

  • Mr. Tom EnglundChief Executive Officer · b. 1976
  • Mr. Anders LarssonCo-Founder & CTO · b. 1973
  • Ms. Anna AhlbergChief Financial Officer · b. 1970
  • Mr. Boaz Tal ), Adv. (CPA, C.P.A.Chief Operating Officer · b. 1968
  • Adele HornIR Manager
  • Mr. Martin JanssonHead of Global Sales · b. 1971
  • Ms. Inbal Mazor-BadichiChief Product & Marketing Officer · b. 1969
  • Mr. Daniel EvestedtHead of Development · b. 1977
  • Mr. Jeffrey Berkley Ph.D.Chief Innovation Officer · b. 1969
  • Mr. Doron ZilbermanExecutive Vice President of International Sales & Educational Products · b. 1962

Financials

Income Statement

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue41.10M46.10M51.80M57.98M65.70M101.52M104.80M366.78M802.54M882.85M884.09M992.34M
Growth (%)-+12.16%+12.36%+11.92%+13.32%+54.51%+3.23%+249.98%+118.81%+10.01%+0.14%+12.25%
Cost of Revenue18.17M-6.30M-6.30M-4.14M-6.22M17.93M16.43M100.84M271.02M269.97M286.19M415.44M
Gross Profit22.93M52.40M58.10M62.12M71.92M83.58M88.36M265.94M531.52M612.88M597.90M576.90M
Gross Margin55.79%113.67%112.16%107.15%109.47%82.33%84.32%72.51%66.23%69.42%67.63%58.14%
Operating Expense25.88M50.60M58.30M65.85M75.99M68.40M68.39M177.19M368.98M423.73M453.58M467.94M
Operating Income-2.95M1.80M-200.00K-3.73M-4.07M15.18M19.97M88.75M162.54M189.15M144.32M108.97M
Operating Margin-7.17%3.90%-0.39%-6.44%-6.19%14.95%19.06%24.20%20.25%21.43%16.32%10.98%
EBITDA2.04M8.90M8.59M-2.25M-1.95M30.36M30.22M115.05M271.30M324.53M224.29M192.34M
EBITDA Margin4.96%19.31%16.57%-3.88%-2.97%29.91%28.84%31.37%33.80%36.76%25.37%19.38%
Net Income-3.04M1.60M3.30M-2.26M-4.52M12.60M15.61M86.25M187.97M233.97M131.65M66.82M
Net Income Margin-7.39%3.47%6.37%-3.89%-6.88%12.41%14.89%23.52%23.42%26.50%14.89%6.73%
R&D4.06M5.92M7.80M8.35M13.74M16.95M16.57M65.71M172.79M181.65M196.11M191.41M
R&D as % of Total Revenue9.89%12.84%15.05%14.40%20.92%16.69%15.81%17.91%21.53%20.57%22.18%19.29%
Interest Expense-200.00K243.00K179.00K7.00K71.00K532.00K22.95M1.30M656.00K5.68M6.28M
Interest Expense % of Total Revenue-0.43%0.47%0.31%0.01%0.07%0.51%6.26%0.16%0.07%0.64%0.63%

Balance Sheet

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets49.33M54.70M63.70M98.92M99.66M456.21M472.27M3.98B4.65B4.70B5.48B4.69B
Total Liabilities11.67M35.10M41.30M13.40M20.28M54.54M45.22M393.06M413.11M357.46M651.03M418.31M
Total Equity18.76M19.60M22.40M85.52M79.38M401.68M427.05M3.59B4.24B4.35B4.83B4.27B
Cash146.21K2.00M3.80M38.54M38.50M69.22M87.16M316.68M433.73M634.37M968.15M616.42M
Total Debt1.46M25.30M28.00M4.04M4.37M9.22M8.12M173.47M15.08M40.02M292.35M78.86M
Net Debt1.32M23.30M24.20M-35.78M-34.13M-66.97M-84.84M-304.61M-419.05M-594.34M-675.81M-537.56M

Cash Flow

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.50M13.40M7.94M6.88M55.20M23.23M39.08M129.49M238.29M137.22M79.80M
Investing Cash Flow--8.40M-11.70M-12.12M-8.64M-210.30M-8.69M-2.73B-34.55M-44.13M-47.53M-134.25M
Financing Cash Flow-2.70M038.95M1.91M185.78M4.21M2.92B17.09M15.85M227.65M-259.68M
Capital Expenditure08.30M11.70M12.12M8.64M8.91M8.69M14.38M34.55M44.13M47.53M11.68M
Free Cash Flow--800.00K1.70M-4.18M-1.76M46.29M14.53M24.71M94.94M194.16M89.69M68.12M
FCF to OCF--10.67%12.69%-52.65%-25.57%83.85%62.57%63.21%73.32%81.48%65.36%85.36%

Earnings

Report DateFeb 22, 2018May 22, 2018Aug 24, 2018Nov 21, 2018Feb 22, 2019May 8, 2019Aug 23, 2019Nov 7, 2019Feb 7, 2020May 5, 2020Aug 21, 2020Nov 5, 2020Feb 11, 2021May 11, 2021Aug 20, 2021Nov 10, 2021Feb 16, 2022May 11, 2022Aug 25, 2022Nov 10, 2022Feb 21, 2023May 16, 2023Aug 24, 2023Nov 9, 2023Feb 20, 2024May 15, 2024Aug 22, 2024Nov 14, 2024Feb 19, 2025May 14, 2025Aug 21, 2025Nov 13, 2025Feb 19, 2026May 20, 2026Aug 18, 2026Nov 12, 2026
EPS Estimate-----------0.050.270.070.170.200.510.350.360.680.860.530.740.741.220.800.720.751.020.600.340.720.850.290.460.68
EPS Actual0.17-0.18-0.07-0.040.12-0.21-0.070.320.27-0.02-0.010.170.310.200.090.821.330.320.520.562.290.980.760.931.920.470.560.840.710.65-0.390.400.690.370.48-
Surprise-----------240.00%14.81%185.71%-47.06%310.00%160.78%-8.57%44.44%-17.65%166.28%84.91%2.70%25.68%57.38%-41.25%-22.22%12.00%-30.39%8.33%-214.71%-44.44%-18.82%27.59%4.35%-
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-market

Key Statistics & Ratios

Market Cap2.72B
Enterprise Value1.88B
Trailing P/E29.92
Forward P/E14.18
Price / Sales2.66
Price / Book0.56
EPS1.78
Book Value89.19
Revenue (TTM)1.02B
Gross Profit (TTM)679.94M
EBITDA184.40M
Profit Margin9.11%
Operating Margin16.38%
Return on Equity2.10%
Return on Assets2.00%
Shares Outstanding51.03M
Shares Float37.07M
Beta0.64
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20233×
0.35Nov 2, 20230.60Jun 15, 20230.38Feb 16, 2023
20223×
0.35Nov 3, 20220.57Jun 16, 20220.36Feb 17, 2022
20213×
0.33Oct 28, 20210.43Jun 17, 20210.25Feb 18, 2021

Stock Splits

  • May 25, 20205:1